Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. on February 16, 2017. The report addresses a specific corporate event rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical trial milestone and does not contain financial statements.
Material Changes
On February 16, 2017, the Company announced the completion of subject enrollment in its Phase 2 clinical trial of NSI-189 for the treatment of major depressive disorder.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the enrollment milestone. The filing does not provide specific financial guidance, updated outlooks, or detailed risk factors beyond the context of the clinical trial progress. A press release dated February 16, 2017, is attached as Exhibit 99.01 for further details.
Investor Verification Checklist
- Verify the full details of the Phase 2 clinical trial enrollment completion in the attached press release (Exhibit 99.01).
- Confirm the timeline for the next expected data readout or interim results from the NSI-189 trial.
- Review recent 10-Q or 10-K filings for the most current financial position, as this 8-K contains no financial data.